Arlington Capital Partners to Sell Riverpoint Medical to Novanta

The strategic sale underscores Riverpoint’s transformation into an industry-leading designer, developer, and manufacturer of next-generation medical devices

WASHINGTON, DC, June 10, 2026 — Arlington Capital Partners (“Arlington”), a Washington, D.C.-area private investment firm specializing in government regulated industries, announced it has agreed to sell Riverpoint Medical (“Riverpoint” or the “Company”) to Novanta Inc. (NASDAQ: NOVT) for a total enterprise value of $1.45 billion, comprised of upfront cash consideration of $1.2 billion and a milestone payment of $250 million in the first quarter of 2027.

Riverpoint is a category leader in high-growth minimally invasive surgical consumables, designing and manufacturing IP-protected, private-label products for leading medical OEM customers. The Company specializes in the production of advanced surgical solutions – including fiber-based, polymer and bioabsorbable devices and structures – critical to life saving medical procedures. Riverpoint’s differentiated position is built on proprietary material science and coating technologies, including osteoconductive coatings and bio-integrative implant designs, and its ability to own the 510(k)-clearance process end-to-end for its customers. The Company has approximately 81,000 total square feet of manufacturing space between its design and manufacturing Center of Excellence in Portland, OR, where the company was founded, and its newly constructed campus in Costa Rica, a leading nearshore medical device manufacturing hub strategically located next to major OEM customer facilities.

Matt Altman, a Managing Partner at Arlington, said, “When we first partnered with Riverpoint, we recognized a company with exceptional engineering talent and differentiated capabilities in surgical fiber and biomedical textiles. Together with the management team, we’ve meaningfully expanded its product portfolio, scaled its manufacturing, and broadened its end markets. Novanta is the ideal home for Riverpoint’s next chapter, and we’re confident the combination will accelerate innovation for customers and create lasting opportunities for the team.”

Since first investing in Riverpoint in 2019, Arlington has helped drive significant business transformation, repositioning the Company around the production of advanced medical solutions and nearly quadrupling revenue virtually all through organic growth. This included partnering with Riverpoint’s management team to expand the leadership bench, enhance commercial capabilities, scale manufacturing operations in the U.S. and grow into new markets by leveraging the power of Costa Rica’s nearshore medical manufacturing hub. Through these initiatives, Riverpoint has evolved into a leading provider of highly engineered surgical solutions and a trusted strategic partner to tier-one medical technology companies, culminating in its acquisition by Novanta.

Doug J. King, CEO of Riverpoint, added: “Arlington was the partner of choice to usher Riverpoint through this stage of growth because of their decades of success investing in and scaling medical manufacturing companies. Our collective success is the direct result of bringing together Riverpoint’s strong management team with Arlington’s deep sector and operational expertise. We want to thank Arlington for its help in taking Riverpoint to new heights and look forward to this next phase of growth with Novanta.”

Gordon Auduong, a Managing Director at Arlington, added, “Riverpoint exemplifies the kind of businesses we set out to build at Arlington — mission-critical products, deep technical capability, and a culture of innovation. We’re proud of what this team has accomplished and are excited to see Riverpoint join Novanta, a strategic partner with the scale and resources to take its technologies to the next level.”

Arlington has an extensive track record of building leading companies in the highly regulated industries critical to the USA’s healthcare infrastructure, government systems and national security, focusing on businesses that save lives, improve the delivery of products and services, and reduce costs for patients and providers. Recent investments in the healthcare sector include Afton Scientific, AVS Bio, CBSET, Cordica Medical, Everest Clinical Research, Grand River Aseptic Manufacturing and Millstone Medical Outsourcing.

Jefferies LLC served as sole financial advisor to Riverpoint Medical and Goodwin Procter LLP served as Riverpoint Medical’s legal advisor.

About Arlington Capital Partners

Arlington Capital Partners is a Washington, D.C.-area private investment firm specializing in government-regulated industries. Focused on the healthcare, aerospace and defense, and government services and technology sectors, the Firm partners with founders and entrepreneurs to build platforms of strategic importance to national priorities. Operating in markets with high barriers to entry, Arlington looks to partner with organizations within these industries that save lives, improve effectiveness, and reduce costs. Since inception in 1999, Arlington has invested in over 200 companies and raised over $14 billion in committed capital. The Firm is currently investing out of its $6 billion Fund VII. For more information, visit Arlington’s website at www.arlingtoncap.com and follow Arlington on LinkedIn.

About Riverpoint Medical

Riverpoint Medical is a category leader in high-growth minimally invasive surgical consumables, designing and manufacturing IP-protected, private-label products for leading medical OEM customers. Riverpoint’s portfolio includes suture anchors, implantable materials, sutures, and surgical instruments, primarily serving sports medicine and cardiovascular surgery applications. The company’s differentiated position is built on proprietary material science and coating technologies, including osteoconductive materials and coatings, and its ability to own the 510(k) clearance process end-to-end for its customers. Riverpoint is headquartered in Portland, Oregon U.S.A., with manufacturing operations in Portland, Oregon and San Jose, Costa Rica. For more information, visit www.rpmed.com